Casiribimab/imdevimab treatment for hemodialysis patients with COVID-19 infection

DOI Web Site Web Site 9 References Open Access
  • Sakai Takashi
    Department of Nephrology, Kidney Disease Center, Tokyo Medical University Hachioji Medical Center
  • Yoshikawa Noriko
    Department of Nephrology, Kidney Disease Center, Tokyo Medical University Hachioji Medical Center
  • Inoue Dan
    Department of Nephrology, Kidney Disease Center, Tokyo Medical University Hachioji Medical Center
  • Uchida Takahiro
    Department of Nephrology, Kidney Disease Center, Tokyo Medical University Hachioji Medical Center
  • Kojima Tadasu
    Department of Nephrology, Kidney Disease Center, Tokyo Medical University Hachioji Medical Center
  • Tomiyasu Tomohiro
    Department of Nephrology, Kidney Disease Center, Tokyo Medical University Hachioji Medical Center
  • Yamada Muneharu
    Department of Nephrology, Kidney Disease Center, Tokyo Medical University Hachioji Medical Center
  • Oda Takashi
    Department of Nephrology, Kidney Disease Center, Tokyo Medical University Hachioji Medical Center

Bibliographic Information

Other Title
  • 新型コロナウイルス感染症の血液透析患者に対するカシリビマブ/イムデビマブの使用経験
  • シンガタ コロナウイルス カンセンショウ ノ ケツエキ トウセキ カンジャ ニ タイスル カシリビマブ/イムデビマブ ノ シヨウ ケイケン

Search this article

Abstract

<p>Neutralizing antibodies are expected to reduce the severity of novel coronavirus disease 2019 (COVID-19) in hemodialysis patients. Among hemodialysis patients with COVID-19 who were admitted to our hospital from August to September 2021, we treated 8 patients who met the criteria for the use of casirivimab/imdevimab (REGEN-COV). The mean age of the patients was 72.8 years, five were male, four had received two doses of the vaccine, and three had received one dose. REGEN-COV was administered on average 3.8 days after the onset of COVID-19. Four patients showed pneumonia before REGEN-COV administration. One patient with 7 risk factors for severe disease other than chronic kidney disease had no evidence of pneumonia before receiving REGEN-COV administration, but developed new signs of oxygen demand and pneumonia after REGEN-COV, and died on day 13. Most of the patients followed a favorable course after REGEN-COV administration, but there were some cases of severe disease. In hemodialysis patients, REGEN-COV may not prevent severe disease when the number of risk factors for severe disease is high. In addition, there are reports that the efficacy of REGEN-COV is weakened with omicron strains, so the number of risk factors for severe disease and virus strains should be taken into consideration when REGEN-COV is used.</p>

Journal

References(9)*help

See more

Related Projects

See more

Keywords

Details 詳細情報について

Report a problem

Back to top